scholarly journals Recombinant Human Soluble Thrombomodulin Treatment for Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Study

Respiration ◽  
2015 ◽  
Vol 89 (3) ◽  
pp. 201-207 ◽  
Author(s):  
Takuma Isshiki ◽  
Susumu Sakamoto ◽  
Arisa Kinoshita ◽  
Keishi Sugino ◽  
Atsuko Kurosaki ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Soluble Thrombomodulin ◽  
Recombinant Human Soluble Thrombomodulin

scholarly journals Therapeutic Role of Recombinant Human Soluble Thrombomodulin for Acute Exacerbation of Idiopathic Pulmonary Fibrosis

Medicina ◽  
2019 ◽  
Vol 55 (5) ◽  
pp. 172 ◽  
Author(s):  
Takuma Isshiki ◽  
Susumu Sakamoto ◽  
Sakae Homma
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Vascular Endothelial Cells ◽  
High Mobility ◽  
Vascular Endothelial ◽  
Therapeutic Role ◽  
Soluble Thrombomodulin ◽  
Recombinant Human Soluble Thrombomodulin

Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is an acute respiratory worsening of unidentifiable cause that sometimes develops during the clinical course of IPF. Although the incidence of AE-IPF is not high, prognosis is poor. The pathogenesis of AE-IPF is not well understood; however, evidence suggests that coagulation abnormalities and inflammation are involved. Thrombomodulin is a transmembranous glycoprotein found on the cell surface of vascular endothelial cells. Thrombomodulin combines with thrombin, regulates coagulation/fibrinolysis balance, and has a pivotal role in suppressing excess inflammation through its inhibition of high-mobility group box 1 protein and the complement system. Thus, thrombomodulin might be effective in the treatment of AE-IPF, and we and other groups found that recombinant human soluble thrombomodulin improved survival in patients with AE-IPF. This review summarizes the existing evidence and considers the therapeutic role of thrombomodulin in AE-IPF.

scholarly journals Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study

2017 ◽  
Vol 126 ◽  
pp. 93-99 ◽  
Author(s):  
Kenta Furuya ◽  
Susumu Sakamoto ◽  
Hiroshige Shimizu ◽  
Muneyuki Sekiya ◽  
Arisa Kinoshita ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation

scholarly journals Acute exacerbation of idiopathic pulmonary fibrosis: a 10-year single-centre retrospective study

2018 ◽  
Vol 5 (1) ◽  
pp. e000342 ◽  
Author(s):  
Masatoshi Yamazoe ◽  
Hiromi Tomioka
Keyword(s):  
Retrospective Study ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Long Term Outcomes ◽  
Hospital Deaths ◽  
Wbc Count ◽  
New Criteria ◽  
Long Term Mortality

IntroductionIn 2016, an international working group proposed a revised definition and new diagnostic criteria for the acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). Based on these criteria, AE-IPF was diagnosed regardless of the presence or absence of a known trigger and categorised as triggered (T-AE) or idiopathic (I-AE) AE-IPF. However, the clinical characteristics of the newly defined AE-IPF and clinical differences between T-AE and I-AE are unresolved.MethodsWe retrospectively analysed 64 patients with AE-IPF (I-AE (42), T-AE (22)) admitted to our hospital over a 10- year period.ResultsI-AE and T-AE cases did not show differences in in-hospital and long-term outcomes (in-hospital mortality: I-AE 52.4%, T-AE 59.1%, p=0.61; long-term mortality: p=0.68). In the I-AE group, significantly more patients received corticosteroid therapy before an AE (I-AE 35.7%, T-AE 4.5%; p=0.01). Significantly more patients in the T-AE group had lung cancer (I-AE 7.1%, T-AE 59.1%, p<0.001). I-AE occurred more frequently in winter while T-AE did not show seasonality. The white blood cell (WBC) count and haemoglobin (Hb) level were independent predictors of in-hospital deaths in I-AE (WBC: OR 1.87; 95% CI 1.09 to 4.95, p=0.01; Hb: OR 0.26, 95%  CI 0.04 to 0.78, p=0.01) but not T-AE.DiscussionWith the introduction of new criteria for AE-IPF, a retrospective study over a 10-year period showed a lack of prognostic difference between I-AE and T-AE. The WBC count and Hb level predicted in-hospital outcome in I-AE cases.

Sign in / Sign up

Export Citation Format

Share Document